1. A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021) Authors: Feagan, B G; Loftus, E V; Danese, S; Vermeire, S; Sandborn, W J; Ritter, T; Mehta, R; Seidler, U; Seibold, F; Beales, I; Kim, H; McNally, J; Yun, C; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 4(2021)Supplement 1 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021) Authors: Peyrin-Biroulet, L; Loftus, E V; Danese, S; Vermeire, S; Sandborn, W J; Fogel, R; Nijhawan, S; Kempinski, R; Filip, R; Hospodarskyy, I; McNally, J; Yun, C; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G; Hibi, T Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 4(2021)Supplement 1 Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗